Long-term survival after resection for non-pancreatic periampullary cancer followed by adjuvant intra-arterial chemotherapy and concomitant radiotherapy

HPB

Volumn 17, Issue 7, 2015, Pages 573-579

  Erdmann, Joris I ^a   Morak, Marjolein J M ^a   Duivenvoorden, Hugo J ^a   Van Dekken, Herman ^a   Kazemier, Geert ^a   Kok, Niels F M ^a   Van Eijck, Casper H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSIMETRY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON PANCREATIC PERIAMPULLARY ADENOCARCINOMA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; ADJUVANT CHEMORADIOTHERAPY; ADVERSE EFFECTS; AGED; AMPULLA OF VATER; BILIARY TRACT SURGERY; COMMON BILE DUCT NEOPLASMS; DISEASE COURSE; INTRAARTERIAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MORTALITY; MULTIVARIATE ANALYSIS; NETHERLANDS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SECONDARY; SURGERY; TIME FACTOR; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AMPULLA OF VATER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT SURGICAL PROCEDURES; CHEMORADIOTHERAPY, ADJUVANT; COMMON BILE DUCT NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84930766585     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12401     Document Type: Article

References (24)

1. Verbeke CS, Gladhaug IP,. (2012) Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg 99: 1036-1049.
2. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al,. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277.
3. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, et al,. (2007) Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 246: 734-740.
4. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al,. (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308: 147-156.
5. Beger HG, Gansauge F, Buchler MW, Link KH,. (1999) Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg 23: 946-949.
6. Link KH, Gansauge F, Rilinger N, Beger HG,. (1997) Celiac artery adjuvant chemotherapy. Results of a prospective trial. Int J Pancreatol 21: 65-69.
7. Maurer CA, Borner MM, Lauffer J, Friess H, Z'Graggen K, Triller J, et al,. (1998) Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer. Int J Pancreatol 23: 181-186.
8. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al,. (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230: 776-782; discussion 782-784.
9. Morak MJ, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J, et al,. (2008) Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg 248: 1031-1041.
10. Sobin LH, Wittekind Ch, eds. (2002) International Union Against Cancer (UICC). In: TNM Classification of Malignant Tumours, 6th edn. New York: Wiley.
11. Vittinghoff E, McCulloch CE,. (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165: 710-718.
12. Klempnauer J, Ridder GJ, Pichlmayr R,. (1995) Prognostic factors after resection of ampullary carcinoma: multivariate survival analysis in comparison with ductal cancer of the pancreatic head. Br J Surg 82: 1686-1691.
13. Smeenk HG, Erdmann J, van Dekken H, van Marion R, Hop WC, Jeekel J, et al,. (2007) Long-term survival after radical resection for pancreatic head and ampullary cancer: a potential role for the EGF-R. Dig Surg 24: 38-45.
14. Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, et al,. (2014) A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol 21: 133-138.
15. van der Zee JA, van Eijck CH, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, et al,. (2011) Angiogenesis: a prognostic determinant in pancreatic cancer? Eur J Cancer 47: 2576-2584.
16. van der Zee JA, ten Hagen TL, Hop WC, van Dekken H, Dicheva BM, Seynhaeve AL, et al,. (2010) Differential expression and prognostic value of HMGA1 in pancreatic head and periampullary cancer. Eur J Cancer 46: 3393-3399.
17. Overman MJ, Zhang J, Kopetz S, Davies M, Zhi-Qin J, Stemke-Hale K, et al,. (2013) Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One 8: e65144.
18. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al,. (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310: 1473-1481.
19. Sultana A, Cox T, Ghaneh P, Neoptolemos JP,. (2012) Adjuvant therapy for pancreatic cancer. Recent Results Cancer Res 196: 65-88.
20. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al,. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281.
21. Hayashibe A, Kameyama M, Shinbo M, Makimoto S,. (2007) Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer. Ann Surg Oncol 14: 190-194.
22. Ishikawa O, Ohhigashi H, Sasaki Y, Furukawa H, Imaoka S,. (1999) Extended pancreatectomy and liver perfusion chemotherapy for resectable adenocarcinoma of the pancreas. Digestion 60 (Suppl. 1): 135-138.
23. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al,. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
24. Morak MJ, Pek CJ, Kompanje EJ, Hop WC, Kazemier G, van Eijck CH,. (2010) Quality of life after adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled study. Cancer 116: 830-836.